A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Transthyretin-Mediated Amyloidosis

Interventions

DRUG

ALN-TTRSC04

ALN-TTRSC04 will be administered by subcutaneous (SC) injection.

DRUG

Placebo

Placebo will be administered by SC injection.

Trial Locations (1)

Clinical Trial Site, London